ArticleVox sanguinis2026
International Society of Blood Transfusion Working Party on Red Cell Immunogenetics and Blood Group Terminology Report of Gothenburg, Barcelona and four virtual business meetings: Update on blood group systems.
Article in Vox sanguinis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Establishing Reference Intervals for White Blood Cell and Absolute Neutrophil Counts in Duffy Null Individuals.Hematology reports · 2026Article
- The Distribution of Kell Blood Group Antigens and Phenotypes (K and k) Among Saudi Blood Donors of King Abdulaziz Medical City - Western Region: A Cross-Sectional Study.Journal of blood medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
Funding
Abstract
BACKGROUND AND
objectivesThe International Society of Blood Transfusion (ISBT) Working Party (WP) on Red Cell Immunogenetics and Blood Group Terminology (RCI&BGT) held six business meetings between December 2021 and June 2024. This report describes the new blood group systems and antigens ratified during these meetings. MATERIALS AND
methodsCandidate systems and antigens were reviewed according to serological, genetic and biological evidence. This evidence was matched against defined criteria, and the acknowledged systems/antigens were assigned a unique identifier.
resultsFour new systems, ER (ISBT 044), CD36 (ISBT 045), ATP11C (ISBT 046) and MAL (ISBT 047), were ratified. CD36 and ATP11C were de novo entries, while ER and MAL systems resolved the genetic basis for the Er and AnWj antigens. Thirteen antigens were added to existing systems: one each to LU (005), YT (011), SC (013), LW (016), KN (022), GLOB (028); an antithetical pair to KEL (006); two antigens to RHAG (030); and three to CTL2 (039). Two CTL2 antigens defined the hitherto unresolved antithetical antigens, Cs
conclusionAs of June 2024, the ISBT has acknowledged 47 blood group systems, comprising 366 antigens. The WP continues to ratify new systems and antigens, which are available on the ISBT website (http://www.isbtweb.org/working-parties/red-cell-immunogenetics-and-blood-group-terminology/).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.